Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this study is that SC teclistamab in combination with SC
daratumumab or lenalidomide will be safe and induce a high rate of VGPR or better in newly
diagnosed multiple myeloma patients
This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of
enrollment for an efficacy and safety interim analysis, interventional Phase 2 study
evaluating the efficacy and safety of a combination with Tec-Dara (Cohort A) or Tec-Len
(Cohort B) in patients with newly diagnosed multiple myeloma who are not eligible for SCT.